Device Debut: Procept Biorobotics Expects To Make A Splash With AquaBeam
Executive Summary
The clinical trial data that earned the AquaBeam Aquablation system de novo clearance from US FDA in December shows Aquablation is as effective as transurethral resection of the prostate at treating symptoms of benign prostate hyperplasia, but carries a lower risk of complications associated.
You may also be interested in...
Procept BioRobotics Believes Aquablation Could Dominate BPH Treatment…If It Gets Coverage
Results of the WATER II trial confirm that Aquablation is a safe and effective treatment of benign prostate hyperplasia for large prostates, and manufacturer Procept BioRobotics is confident the procedure will eventually displace all other prostate resection techniques because it is easy for surgeons to learn.
Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2018
Device fundraising in the first quarter totaled $7.6 billion, thanks to Siemens Healthineers $5.2 billion IPO, which accounted for more than two-thirds of the total. Q1 M&A activity reached $6.7 billion, a significant rise from Q4's $3.9 billion. Similarly, aggregate first quarter diagnostics financings (at $1.5 billion) and M&As (at $543 million) also experienced substantial increases over the previous quarter.
Medicare Bonus Payments: CMS Plans To End Three, But Considers Seven New-Tech Add-On Payments For FY 2019
While the US Medicare agency is proposing to end hospital inpatient new-technology add-on payments for Edwards Lifesciences’ and LivaNova’s minimally surgical valves, and for WL Gore's endoprosthesis aneurysm device, it is evaluating possible bonus payments for 7 more devices beginning Oct. 1.